ALKBH5 Facilitates Hypoxia-Induced Paraspeckle Assembly and IL8 Secretion to Generate an Immunosuppressive Tumor Microenvironment
- PMID: 34670781
- DOI: 10.1158/0008-5472.CAN-21-1456
ALKBH5 Facilitates Hypoxia-Induced Paraspeckle Assembly and IL8 Secretion to Generate an Immunosuppressive Tumor Microenvironment
Abstract
The dynamic changes of RNA N6-methyl-adenosine (m6A) during cancer progression contribute to quick adaption to microenvironmental changes. Here, we profiled the cancer cell m6A dynamics in the hypoxic tumor niche and its pathological consequences in glioblastoma multiforme (GBM). The m6A demethylase ALKBH5 was induced in GBM models under hypoxic conditions and was associated with a hypoxic gene signature in GBM patient samples. Depletion or inactivation of ALKBH5 in GBM cells significantly suppressed hypoxia-induced tumor-associated macrophage (TAM) recruitment and immunosuppression in allograft tumors. Expression and secretion of CXCL8/IL8 were significantly suppressed in ALKBH5-deficient tumors. However, ALKBH5 did not regulate CXCL8 m6A directly. Instead, hypoxia-induced ALKBH5 erased m6A deposition from the lncRNA NEAT1, stabilizing the transcript and facilitating NEAT1-mediated paraspeckle assembly, which led to relocation of the transcriptional repressor SFPQ from the CXCL8 promoter to paraspeckles and, ultimately, upregulation of CXCL8/IL8 expression. Accordingly, ectopic expression of CXCL8 in ALKBH5-deficient GBM cells partially restored TAM recruitment and tumor progression. Together, this study links hypoxia-induced epitranscriptomic changes to the emergence of an immunosuppressive microenvironment facilitating tumor evasion. SIGNIFICANCE: Hypoxia induces tumor immune microenvironment remodeling through an ALKBH5-mediated epigenetic and epitranscriptomic mechanism, providing potential immunotherapeutic strategies for treating glioblastoma.
©2021 American Association for Cancer Research.
Similar articles
-
The disordered C terminus of ALKBH5 promotes phase separation and paraspeckles assembly.J Biol Chem. 2023 Aug;299(8):105071. doi: 10.1016/j.jbc.2023.105071. Epub 2023 Jul 18. J Biol Chem. 2023. PMID: 37474102 Free PMC article.
-
m6A Demethylase ALKBH5 Maintains Tumorigenicity of Glioblastoma Stem-like Cells by Sustaining FOXM1 Expression and Cell Proliferation Program.Cancer Cell. 2017 Apr 10;31(4):591-606.e6. doi: 10.1016/j.ccell.2017.02.013. Epub 2017 Mar 23. Cancer Cell. 2017. PMID: 28344040 Free PMC article.
-
ALKBH5 promotes the progression of infantile hemangioma through regulating the NEAT1/miR-378b/FOSL1 axis.Mol Cell Biochem. 2022 May;477(5):1527-1540. doi: 10.1007/s11010-022-04388-2. Epub 2022 Feb 18. Mol Cell Biochem. 2022. PMID: 35182329
-
Demethylases in tumors and the tumor microenvironment: Key modifiers of N6-methyladenosine methylation.Biomed Pharmacother. 2024 May;174:116479. doi: 10.1016/j.biopha.2024.116479. Epub 2024 Mar 26. Biomed Pharmacother. 2024. PMID: 38537580 Review.
-
Macrophages and microglia: the cerberus of glioblastoma.Acta Neuropathol Commun. 2021 Mar 25;9(1):54. doi: 10.1186/s40478-021-01156-z. Acta Neuropathol Commun. 2021. PMID: 33766119 Free PMC article. Review.
Cited by
-
Exploration and validation of a combined Hypoxia and m6A/m5C/m1A regulated gene signature for prognosis prediction of liver cancer.BMC Genomics. 2023 Dec 14;24(1):776. doi: 10.1186/s12864-023-09876-3. BMC Genomics. 2023. PMID: 38097948 Free PMC article.
-
Crosstalk among m6A RNA methylation, hypoxia and metabolic reprogramming in TME: from immunosuppressive microenvironment to clinical application.J Hematol Oncol. 2022 Jul 6;15(1):84. doi: 10.1186/s13045-022-01304-5. J Hematol Oncol. 2022. PMID: 35794625 Free PMC article. Review.
-
Pumilio RNA binding family member 1 deficiency activates anti-tumor immunity in hepatocellular carcinoma via restraining M2 macrophage polarization.Cell Cycle. 2024 Mar;23(6):682-692. doi: 10.1080/15384101.2024.2355825. Epub 2024 May 24. Cell Cycle. 2024. PMID: 38794797
-
Epigenetic regulation in the tumor microenvironment: molecular mechanisms and therapeutic targets.Signal Transduct Target Ther. 2023 May 22;8(1):210. doi: 10.1038/s41392-023-01480-x. Signal Transduct Target Ther. 2023. PMID: 37217462 Free PMC article. Review.
-
RNA Modifications Meet Tumors.Cancer Manag Res. 2022 Nov 22;14:3223-3243. doi: 10.2147/CMAR.S391067. eCollection 2022. Cancer Manag Res. 2022. PMID: 36444355 Free PMC article. Review.
References
-
- Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med. 2008;359:492–507.
-
- Lim M, Xia Y, Bettegowda C, Weller M. Current state of immunotherapy for glioblastoma. Nat Rev Clin Oncol. 2018;15:422–42.
-
- Quail DF, Joyce JA. The microenvironmental landscape of brain tumors. Cancer Cell. 2017;31:326–41.
-
- Qiu GZ, Jin MZ, Dai JX, Sun W, Feng JH, Jin WL. Reprogramming of the tumor in the hypoxic niche: the emerging concept and associated therapeutic strategies. Trends Pharmacol Sci. 2017;38:669–86.
-
- Hu J, Xiao Q, Dong M, Guo D, Wu X, Wang B. Glioblastoma immunotherapy targeting the innate immune checkpoint CD47–SIRPalpha axis. Front Immunol. 2020;11:593219.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources